Full-Time

Community Navigator

ATTR-CM & Sickle Cell Disease

Posted on 9/9/2026

Deadline 9/16/26
Pfizer

Pfizer

10,001+ employees

Biopharmaceutical company develops medicines and vaccines

Compensation Overview

$162.9k - $271.5k/yr

+ 20% bonus target + Share-based long-term incentive program

No H1B Sponsorship

New Mexico, USA + 7 more

More locations: Texas, USA | Montana, USA | Mississippi, USA | Arkansas, USA | Oklahoma, USA | Missouri, USA | Louisiana, USA

Remote

Remote role with travel up to 50%, including weekends and evenings.

Bachelor's

Category
Social & Community Services (1)
Required Skills
Patient Education

Get referred to Pfizer

See people who can refer or advise you

Requirements
  • A B.S. or B.A. degree is required.
  • A minimum of 7–10 years of pharmaceutical or related industry experience is required.
  • Experience with transthyretin amyloid cardiomyopathy and/or Sickle Cell Disease is required.
  • Ability to build and maintain disease-state and community knowledge across more than one therapeutic area and prioritize effectively across concurrent responsibilities.
  • Demonstrated communication, listening, and presentation skills.
  • Ability to work in regulated environments and adhere to compliance guidelines.
  • A track record of broad collaboration with diverse clients and stakeholders.
  • Experience in responsible business practices and compassionate communication.
  • Experience engaging diverse and underserved patient communities with cultural humility.
  • Familiarity with Pfizer and industry compliance guidelines for working with Medical and Access & Reimbursement colleagues.
  • Ability to deliver concise, meaningful presentations with integrity and empathy.
  • Strong attention to detail, organizational, and business skills.
  • Willingness to travel up to 50%, including weekends and evenings.
  • Candidates must be authorized to be employed in the United States by any employer.
  • The position requires permanent work authorization in the United States.
Responsibilities
  • Educate patients and caregivers about transthyretin amyloid cardiomyopathy and Sickle Cell Disease, treatment options, local and regional support offerings, and health and wellness resources.
  • Provide ongoing education and disease-state awareness throughout the patient journey, tailored to the distinct needs of each community.
  • Allocate time and effort across both therapeutic areas in line with team priorities, maintaining current disease-state knowledge, approved resources, and community relationships.
  • Assist patients in navigating care by connecting them to relevant resources within their communities and at Pfizer.
  • Engage underserved communities, with particular attention to populations disproportionately affected by Sickle Cell Disease, to support equitable access to education, resources, and support.
  • Coordinate with Key Account Directors, management, and cross-functional partners across two brand teams.
  • Set objectives, manage complex projects, and oversee ongoing activities within the Business Unit.
  • Develop collaborations and partnerships with healthcare systems, healthcare professionals and educators, and advocacy partners.
  • Serve as a subject matter expert in both therapeutic areas and share knowledge across the organization.
  • Develop solutions to complex problems, champion innovation, and implement new ideas, processes, or products.
  • Provide guidance and educational resources to address patient questions and information needs.
  • Support patients in navigating care by connecting them to appropriate resources.
  • Share information on emerging treatments and the treatment journey to facilitate shared decision-making.
  • Coordinate with advocacy and support teams and attend events to present approved educational content.
  • Use motivational interviewing to identify patient needs and tailor engagement to each community.
  • Offer in-person and virtual engagement for opted-in patients using print and digital resources.
  • Build trust and provide ongoing support for patients to take informed next steps.
  • Refer patients and caregivers to local health and wellness organizations.
  • Operate within a geographic region to educate and connect patients to healthcare resources.
  • Adhere to regulations and policies while collaborating with legal and compliance teams.
  • Present the Community Navigator role and Pfizer support resources at local, regional, and national events.
  • Partner with internal teams to meet patient needs and provide educational content to support groups.
  • Engage with patients and caregivers through various communication channels.
  • Provide local insights to inform the development of patient engagement materials and support resources.
  • Organize travel and materials for events in a timely manner.
  • Triage patients to reimbursement resources as needed without providing reimbursement support for Pfizer treatments.
Desired Qualifications
  • A clinical background such as RN, APRN, NP, ARNP, ACSW, LCSW, or MPH is preferred.
  • Knowledge of transthyretin amyloid cardiomyopathy and/or Sickle Cell Disease and patient/public advocacy is preferred.
  • Experience with hematology, rare disease, or cardiology patient communities is preferred.
  • Living in the specified geography is preferred for this remote, field-based role.
  • Bilingual proficiency in certain areas is preferred.

Pfizer is a global biopharmaceutical company that discovers, develops, manufactures, and sells medicines and vaccines for a range of health needs, including vaccines, oncology, and other specialized therapies. Its products work by using biological mechanisms to prevent or treat diseases—vaccines train the immune system to fight infections, while medicines target cancer and other conditions. Pfizer differentiates itself through its large worldwide footprint, broad portfolio across multiple therapeutic areas, and partnerships (notably with BioNTech) that expanded its reach in vaccines and cutting-edge therapies. The company also engages in public health initiatives, such as efforts to provide vaccines to underserved populations. Pfizer’s broad goal is to improve global health by delivering safe and effective medicines and vaccines through research, development, and wide international distribution.

Company Size

10,001+

Company Stage

IPO

Headquarters

New York City, New York

Founded

1849

Get referred to Pfizer

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • FDA approved Pfizer-BioNTech’s XFG COVID vaccine on August 27, 2026 for fall shipping.
  • Pfizer raised 2026 revenue guidance to $60.5 billion-$62.5 billion on August 4, 2026.
  • Padcev and Lorbrena grew in Q2 2026, proving post-Seagen oncology momentum.

What critics are saying

  • Eliquis loses U.S. exclusivity in 2028, opening a rapid generic cliff.
  • Arbutus filed international LNP patent suits on July 16, 2026 against Pfizer-BioNTech.
  • Comirnaty and Paxlovid remain shrinking as FDA narrows eligibility and COVID demand fades.

What makes Pfizer unique

  • Pfizer’s Seagen acquisition gives it a stronger oncology engine than pure-vaccine peers.
  • Eliquis and Vyndaqel diversify revenue beyond COVID, with Q2 2026 growth.
  • Pfizer’s global commercial scale still pushes products through pharmacies, hospitals, and governments.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

401(k) Retirement Plan

401(k) Company Match

Paid Vacation

Paid Sick Leave

Paid Holidays

Hybrid Work Options

Relocation Assistance

Growth & Insights and Company News

Headcount

6 month growth

-5%

1 year growth

-5%

2 year growth

-5%
Yahoo Finance
Sep 8th, 2026
AbbVie beats Pfizer as top dividend stock with 53-year payout streak and 203% growth

AbbVie offers a smarter long-term dividend investment than Pfizer, despite Pfizer's higher 6.1% yield. AbbVie holds Dividend King status with 53 consecutive years of dividend increases and raised its payout by 5.5% this year to $1.73 per share. Over the past decade, AbbVie increased its dividend by more than 203% compared to Pfizer's 51%. AbbVie's revenue grew 138% during this period, whilst Pfizer's rose just 18%. AbbVie successfully navigated Humira's patent cliff through home-grown immunology drugs Skyrizi and Rinvoq. By 2025, these two drugs generated combined annual sales exceeding $25 billion, replacing Humira's peak revenue and pushing total company revenue to record highs. AbbVie's free-cash-flow dividend payout ratio stands at 65%, lower than Pfizer's 89%.

Yahoo Finance
Aug 28th, 2026
Pfizer's updated COVID vaccine ships as FDA approves narrower rollout for over-65s and high-risk groups

Pfizer received FDA approval for its updated Comirnaty COVID-19 vaccine on Thursday, with deliveries to pharmacies and clinics beginning immediately. The company's shares were trading at $27.9079 on 28 August. However, the market opportunity has significantly narrowed from pandemic levels. Eligibility is now limited to adults aged 65 and older, plus higher-risk patients aged 5 through 64. Despite Comirnaty having distributed over five billion doses worldwide historically, today's revenue potential is considerably more constrained. Pfizer faces competition from Moderna and the Novavax-Sanofi protein vaccine for this smaller patient pool. The company's current share price sits 5.27% above its estimated value of $26.51, suggesting investors are paying a premium before actual uptake and commercial results become clear.

Associated Press
Aug 27th, 2026
FDA approves Pfizer-BioNTech XFG-adapted COVID-19 vaccine for high-risk groups

Pfizer and BioNTech have received US Food and Drug Administration (FDA) approval for their 2026-2027 COVID-19 vaccine targeting the XFG variant. The vaccine is approved for adults aged 65 and older, and individuals aged 5 to 64 with underlying conditions that increase risk of severe COVID-19 outcomes. The FDA approval is based on clinical, non-clinical and real-world data demonstrating the vaccine generates strong immune responses against currently circulating SARS-CoV-2 variants, including XFG and other contemporary lineages. The XFG variant was selected following FDA guidance for fall 2026 vaccine composition. The vaccine will begin shipping immediately and will be available in US pharmacies, hospitals and clinics within days. To date, more than five billion doses of COMIRNATY have been distributed globally.

Yahoo Finance
Aug 24th, 2026
Pfizer and J&J navigate patent cliffs with newer drugs offsetting blockbuster losses

Pfizer and Johnson & Johnson are navigating patent cliffs as key drugs lose exclusivity, with their latest results showing differing stages of transition. Pfizer's revenue excluding COVID products grew 5% operationally in Q2 2026, with newer medicines like Padcev and Vyndaqel contributing. The company expects $9.7 billion in cost savings through 2029 to support margins during the transition. Johnson & Johnson's Innovative Medicine sales rose 7.8%, despite Stelara revenue declining 55%. Tremfya sales surged 72.5% to $2 billion, helping offset losses alongside growth from oncology and neuroscience products. Johnson & Johnson raised 2026 guidance, with reported sales expected to reach $101.1 billion and adjusted EPS of $11.68. Its MedTech division provides additional diversification that pure pharmaceutical company Pfizer lacks, suggesting Johnson & Johnson's transition is more advanced.

Yahoo Finance
Aug 19th, 2026
Intel CEO invests $10M in shares as chipmaker posts 25% revenue growth driven by AI demand

Intel CEO Lip-Bu Tan purchased nearly $10 million worth of shares as part of the chipmaker's recent stock offering, signalling confidence in the company's turnaround. Intel recently reported revenues of $16.1 billion, growing 25% year-over-year, with its Data Centre and AI business unit seeing revenue surge nearly 60% to $6.3 billion. CoStar Group founder and CEO Andrew Florance purchased 83,300 shares totalling roughly $2.5 million. Pfizer CEO Albert Bourla similarly invested, purchasing 38,000 shares for just over $1 million. These insider purchases reflect executives' confidence in their companies' longer-term outlook, with investors often viewing such moves as a positive signal.